Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
Panelists discuss how balancing treatment intensity with quality of life remains a critical challenge in advanced gastric cancers (GCs) and how implementing biomarker-driven approaches such as PD-L1 combined positive score (CPS) testing faces practical hurdles in clinical settings. Key considerations include optimizing patient outcomes while managing adverse effects and addressing barriers such as testing accessibility, result turnaround time, and standardization of biomarker interpretation.
EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
Now Viewing
EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
EP: 7.Key Takeaways and Future in Advanced Gastric Cancer Treatment
EP: 8.Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
- How might these findings shape discussions about the balance between treatment intensity and maintaining patients’ quality of life in advanced GC/gastroesophageal junction cancer/esophageal adenocarcinoma?
- What barriers might exist in applying biomarker-driven approaches, such as PD-L1 CPS, in real-world clinical settings, and how can they be addressed?
Recent Videos
Related Content
